1. Home
  2. LPTX vs ELWS Comparison

LPTX vs ELWS Comparison

Compare LPTX & ELWS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LPTX
  • ELWS
  • Stock Information
  • Founded
  • LPTX 2011
  • ELWS 2018
  • Country
  • LPTX United States
  • ELWS Japan
  • Employees
  • LPTX N/A
  • ELWS N/A
  • Industry
  • LPTX Biotechnology: Biological Products (No Diagnostic Substances)
  • ELWS
  • Sector
  • LPTX Health Care
  • ELWS
  • Exchange
  • LPTX Nasdaq
  • ELWS Nasdaq
  • Market Cap
  • LPTX 14.7M
  • ELWS 12.1M
  • IPO Year
  • LPTX N/A
  • ELWS 2023
  • Fundamental
  • Price
  • LPTX $0.31
  • ELWS $4.18
  • Analyst Decision
  • LPTX Hold
  • ELWS
  • Analyst Count
  • LPTX 1
  • ELWS 0
  • Target Price
  • LPTX N/A
  • ELWS N/A
  • AVG Volume (30 Days)
  • LPTX 661.1K
  • ELWS 392.6K
  • Earning Date
  • LPTX 08-19-2025
  • ELWS 08-19-2025
  • Dividend Yield
  • LPTX N/A
  • ELWS N/A
  • EPS Growth
  • LPTX N/A
  • ELWS N/A
  • EPS
  • LPTX N/A
  • ELWS N/A
  • Revenue
  • LPTX N/A
  • ELWS $3,069,669.00
  • Revenue This Year
  • LPTX N/A
  • ELWS N/A
  • Revenue Next Year
  • LPTX N/A
  • ELWS N/A
  • P/E Ratio
  • LPTX N/A
  • ELWS N/A
  • Revenue Growth
  • LPTX N/A
  • ELWS 144.46
  • 52 Week Low
  • LPTX $0.22
  • ELWS $1.04
  • 52 Week High
  • LPTX $4.79
  • ELWS $10.50
  • Technical
  • Relative Strength Index (RSI)
  • LPTX 43.86
  • ELWS 51.37
  • Support Level
  • LPTX $0.30
  • ELWS $3.50
  • Resistance Level
  • LPTX $0.37
  • ELWS $10.50
  • Average True Range (ATR)
  • LPTX 0.03
  • ELWS 1.53
  • MACD
  • LPTX -0.00
  • ELWS -0.01
  • Stochastic Oscillator
  • LPTX 28.53
  • ELWS 24.58

About LPTX Leap Therapeutics Inc.

Leap Therapeutics Inc is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. The company's key clinical-stage drug candidate is sirexatamab (DKN-01), which targets Dickkopf-related protein 1 (DKK1) and is being studied in a clinical trial in patients with colorectal cancer. In addition, it also has a preclinical program to develop a proprietary monoclonal antibody, called FL-501 which works by inhibiting the GDF-15 protein.

About ELWS Earlyworks Co. Ltd.

Earlyworks Co Ltd is a blockchain-based technology company. It builds products, delivers services, and develops solutions based on a proprietary grid ledger system to leverage blockchain technology in various business settings, including advertisement tracking, online visitor management, and sales of non-fungible tokens. The company's customers represent a diverse range of industries, such as information technology, shipping, real estate, entertainment, cosmetics, and chemical products.

Share on Social Networks: